Is Immune Checkpoint Inhibition Part of Standard Therapy for Stage III Non-Small Cell Lung Cancer?

被引：0
|
作者：
Patel, Jyoti D. [1 ]
Chmura, Steven J. [2 ]
机构：
[1] Univ Chicago, Dept Med, Hematol Oncol Sect, Chicago, IL 60637 USA
[2] Univ Chicago, Dept Radiat Oncol, Chicago, IL 60637 USA
来源：
CANCER | 2018年 / 124卷 / 14期
关键词：
RANDOMIZED PHASE-III; CONSOLIDATION; RADIOTHERAPY; CONCURRENT; TRIAL; PEMBROLIZUMAB; CISPLATIN; RADIATION; DOCETAXEL;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：2878 / 2880
页数：3
相关论文
共 50 条
  • [31] Neoadjuvant and adjuvant therapy for Stage III non-small cell lung cancer
    Watanabe, Shun-ichi
    Nakagawa, Kazuo
    Suzuki, Kenji
    Takamochi, Kazuya
    Ito, Hiroyuki
    Okami, Jiro
    Aokage, Keiju
    Saji, Hisashi
    Yoshioka, Hiroshige
    Zenke, Yoshitaka
    Aoki, Tadashi
    Tsutani, Yasuhiro
    Okada, Morihito
    [J]. JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2017, 47 (12) : 1112 - 1118
  • [32] Should chemotherapy plus immune checkpoint inhibition be the standard front-line therapy for patients with metastatic non-small cell lung cancer?
    Goldberg, Sarah B.
    Herbst, Roy S.
    [J]. CANCER, 2018, 124 (24) : 4592 - 4596
  • [33] Evolution of cystic airspaces lung lesions on immune checkpoint inhibition in non-small cell lung cancer
    Parisi, Claudia
    Lamberti, Giuseppe
    Zompatori, Maurizio
    Gelsomino, Francesco
    Salvagni, Stefania
    Sperandi, Francesca
    Ardizzoni, Andrea
    [J]. JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2020, 8 (02)
  • [34] Immune Checkpoint Inhibition in Non-metastatic Non-small Cell Lung Cancer: Chance for Cure?
    David F. Heigener
    Martin Reck
    [J]. Drugs, 2019, 79 : 1937 - 1945
  • [35] Immune Checkpoint Inhibition in Non-metastatic Non-small Cell Lung Cancer: Chance for Cure?
    Heigener, David F.
    Reck, Martin
    [J]. DRUGS, 2019, 79 (18) : 1937 - 1945
  • [36] The new era of immune checkpoint inhibition and target therapy in early-stage non-small cell lung cancer. A review of the literature
    Catania, Chiara
    Muthusamy, Bharathi
    Spitaleri, Gianluca
    del Signore, Ester
    Pennell, Nathan A.
    [J]. CLINICAL LUNG CANCER, 2022, 23 (02) : 108 - 115
  • [37] Operability and Pathological Response of Non-Small Cell Lung Cancer (NSCLC) after Neoadjuvant Therapy with Immune Checkpoint Inhibition
    Luecke, E.
    Ganzert, C.
    Foellner, S.
    Waesche, A.
    Jechorek, D.
    Schoeder, V.
    Walles, T.
    Genseke, P.
    Schreiber, J.
    [J]. PNEUMOLOGIE, 2020, 74 (11): : 766 - 772
  • [38] Neoadjuvant Immune Checkpoint Inhibitors in Non-small Cell Lung Cancer
    Xue, Chongxiang
    Dong, Huijing
    Chen, Ying
    Lu, Xingyu
    Zheng, Shuyue
    Cui, Huijuan
    [J]. JCPSP-JOURNAL OF THE COLLEGE OF PHYSICIANS AND SURGEONS PAKISTAN, 2022, 32 (06): : 779 - 788
  • [39] Highlights on immune checkpoint inhibitors in non-small cell lung cancer
    Shen, Meng
    Ren, Xiubao
    [J]. TUMOR BIOLOGY, 2017, 39 (03)
  • [40] Immune checkpoint inhibitors in advanced non-small cell lung cancer
    Fabre, Elizabeth
    Pecuchet, Nicola
    Cadranel, Jacques
    [J]. BULLETIN DU CANCER, 2016, 103 : S138 - S143
12345